^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Solid Tumor

    Related cancers:
    21h
    Integrated scRNA-seq and bulk transcriptomics identify an amino acid metabolism-associated prognostic signature and highlight FUS as a potential driver in prostate cancer progression. (PubMed, Funct Integr Genomics)
    Our study establishes a clinically actionable amino acid metabolic signature and nomogram for PCa risk stratification, while suggesting FUS as a candidate therapeutic target. These findings bridge computational discovery with mechanistic validation, providing novel insights into the amino acid metabolic dependencies that govern prostate cancer (PCa) progression.
    Journal
    |
    FUS (FUS RNA Binding Protein)
    21h
    New Sinomenine Derivative as a Potential Drug for Cervical Cancer via Inducing Ferroptosis. (PubMed, Arch Pharm (Weinheim))
    Molecular docking simulation results suggested that 16 can interact with ferroptosis-related proteins via the van der Waals force, and cation-π, anion-π, and hydrogen bonding interactions. In brief, Compound 16 may be a potentially useful drug for the treatment of cervical cancer, as it induces ferroptosis in HeLa cells by inhibiting FTH1 expression and the SLC7A11/GSH/GPX4 pathway.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • FTH1 (Ferritin Heavy Chain 1)
    23h
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, I-Mab Biopharma US Limited | N=168 --> 330 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    Opdivo (nivolumab) • Imfinzi (durvalumab) • givastomig (TJ-CD4B)
    23h
    Effects of Pranayama Breathing Technique on Stress Level, Sleep Quality, and Quality of Life Among Older Adults (clinicaltrials.gov)
    P=N/A, N=74, Completed, Namik Kemal University
    New trial • HEOR
    23h
    Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Feb 2027
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61
    |
    Mekinist (trametinib) • omipalisib (GSK2126458)
    23h
    NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, M.D. Anderson Cancer Center | N=36 --> 6 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Firmagon (degarelix)
    24h
    Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (clinicaltrials.gov)
    P1, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    carboplatin • paclitaxel • veliparib (ABT-888)
    24h
    TOPP: Timing of Post-prostatectomy PSMA Imaging (clinicaltrials.gov)
    P2, N=4, Completed, University Health Network, Toronto | Recruiting --> Completed | N=40 --> 4
    Trial completion • Enrollment change
    1d
    A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC (clinicaltrials.gov)
    P2, N=80, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Keytruda (pembrolizumab) • trastuzumab brengitecan (BL-M07D1)
    1d
    UPC: Utrecht Prostate Cohort for Cancer Treatment Intervention Studies and Long-term Evaluation (clinicaltrials.gov)
    P=N/A, N=1500, Recruiting, UMC Utrecht | Trial primary completion date: Feb 2023 --> Feb 2030
    Trial primary completion date
    1d
    EMBRACE: Large Language Model-Based Emotional Management for Breast Cancer Patients (clinicaltrials.gov)
    P=N/A, N=440, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New trial
    1d
    Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date